UK court sends Pfizer/Flynn back to the CMA
The Court of Appeal of England and Wales has held that the UK’s competition enforcer did not sufficiently prove that two drug companies' prices were excessive, but backed the enforcer that it does not need to construct a hypothetical benchmark price.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10